Dichloromethylene diphosphonate (Cl2MDP), an inhibitor of oestoclast activity, was evaluated for its ability to decrease the excessive mobilization of skeletal calcium that complicates multiple myeloma. Ten patients with active myeloma, wide-spread bone disease, and hypercalciuria were studied in a double-blind, placebo-controlled, crossover-designed trial in which they took Cl2MDP for eight weeks and placebos for eight weeks. Two patients died during the placebo phase; of eight patients who received Cl2MDP, seven had rapid, sustained, and highly significant (P less than 0.001) decreases in urinary excretion of calcium. Six also had significant decreases in hydroxyproline excretion, and five reported lessening of skeletal pain. On patient did not respond. Although the patients received concurrent chemotherapy during the study, concentrations of myeloma proteins actually increased or decreased only slightly, indicating the declines in hypercalciuria resulted from Cl2MDP and not from improvement in the underlying disease. We conclude that Cl2MDP is a potentially useful inhibitor of osteoclast-mediated bone erosion in multiple myeloma.
This article has been cited by other articles:
Terpos, E., Sezer, O., Croucher, P. I., Garcia-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Blade, J., Cavo, M., Delforge, M., Dimopoulos, M.-A., Facon, T., Macro, M., Waage, A., Sonneveld, P.
(2009). The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol
20: 1303-1317
[Abstract][Full Text]
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., Blacklock, H. A., Bell, R., Simeone, J., Reitsma, D. J., Heffernan, M., Seaman, J., Knight, R. D., The Myeloma Aredia Study Group,
(1996). Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma. NEJM
334: 488-493
[Abstract][Full Text]
Osserman, E. F., Merlini, G., Butler, V. P. Jr
(1987). Multiple Myeloma and Related Plasma Cell Dyscrasias. JAMA
258: 2930-2937
[Abstract]
Attardo-Parrinello, G., Merlini, G., Pavesi, F., Crema, F., Fiorentini, M. L., Ascari, E.
(1987). Effects of a New Aminodiphosphonate (Aminohydroxybutylidene Diphosphonate) in Patients With Osteolytic Lesions From Metastases and Myelomatosis: Comparison With Dichloromethylene Diphosphonate. Arch Intern Med
147: 1629-1633
[Abstract]
Schiller, J. H., Rasmussen, P., Benson, A. B. III, Witte, R. S., Bockman, R. S., Harvey, H. A., Siris, E. S., Citrin, D. L., Greco, F. A., Stock, J. L.
(1987). Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia. Arch Intern Med
147: 963-966
[Abstract]
Ryzen, E., Martodam, R. R., Troxell, M., Benson, A., Paterson, A., Shepard, K., Hicks, R.
(1985). Intravenous Etidronate in the Management of Malignant Hypercalcemia. Arch Intern Med
145: 449-452
[Abstract]
HEMATOLOGY COMMITTEE,
(1982). Hematology: An Annotated Bibliography of Recent Literature: References to Journal Articles and Other Papers. ANN INTERN MED
97: 459-465
[Abstract]
BILEZIKIAN, J. P.
(1982). The Medical Management of Primary Hyperparathyroidism. ANN INTERN MED
96: 198-202
[Abstract]
SHANE, E., BAQUIRAN, D. C., BILEZIKIAN, J. P.
(1981). Effects of Dichloromethylene Diphosphonate on Serum and Urinary Calcium in Primary Hyperparathyroidism. ANN INTERN MED
95: 23-27
[Abstract]
JACOBS, T. P., SIRIS, E. S., BILEZIKIAN, J. P., BAQUIRAN, D. C., SHANE, E., CANFIELD, R. E.
(1981). Hypercalcemia of Malignancy: Treatment with Intravenous Dichloromethylene Diphosphonate. ANN INTERN MED
94: 312-316
[Abstract]
Previous
